Latest Daily News

More Stories
May 25, 2017

During the Education Session “Tobacco Cessation and CT Screening Recommendations for Patients With Lung Cancer,” to be held on June 4, experts will discuss strategies for implementing lung cancer screening programs.

Read more
May 25, 2017

How to best manage issues that are common in older patients with advanced non–small cell lung cancer will be the focus of the Education Session “Lung Cancer in the Older Population: Caring for the Whole Patient."

Read more
May 25, 2017

This editorial discusses the role of RET rearrangements in non–small cell lung cancer (NSCLC) and the latest advances in RET fusion–targeting approaches.

Read more
April 7, 2017

Vamsidhar Velcheti, MD, and his team have been investigating why some people respond to immunotherapy while others do not.

Read more
June 6, 2016

Results from a phase I study conducted in patients with relapsed or refractory metastatic disease revealed that single-agent treatment with the antibody-drug conjugate delivered a powerful blow to tumors bearing delta-like protein 3.

Read more

June 7, 2016

The NLST launched lung cancer screening, and since then, guidelines and recommendations have continued to evolve. Experts discussed rationale for lung screening, practical issues with screening implementation, and the enormous opportunity of addressing tobacco use during an Education Session.

Read more

June 7, 2016

The combination of the checkpoint inhibitor nivolumab with or without the anti–CTLA-4 ipilimumab resulted in durable objective responses for relapsed small cell lung cancer, regardless of platinum sensitivity or tumor PD-L1 expression.

Read more
June 7, 2016

Immune checkpoint inhibitors show promise in combating lung cancer and other malignancies by altering the tumor microenvironment and blocking the immune system evasion that allows cancers to grow and proliferate.

Read more
June 7, 2016

Immunotherapy with CD19+ chimeric antigen receptor T cells made up of a defined 1:1 ratio of CD8+ and CD4+ resulted in a durable complete response.

Read more
June 7, 2016

When Breath Becomes Air,  a New York Times bestselling novel examining the interplay between life and death for patients with cancer, was selected for the 2016  ASCO Book Club. 

Read more
June 7, 2016

Dr. Paul A. Bunn, Jr., is honored with the 2016 David A. Karnofsky Memorial Award and Lecture for establishing new lung cancer diagnostics and treatment strategies, which have led to dramatically improved outcomes in patients with lung cancer. 

Read more
May 26, 2016

The Conquer Cancer Foundation of ASCO has received generous support from Lung Cancer Alliance to fund a 2016 and 2017 Young Investigator Award in lung cancer.

Read more

May 26, 2016

Elderly patients with advanced cancers are generally undertreated, particularly in advanced NSCLC. Why does this disparity exist, and have we made progress in the past 5 years?

Read more

May 26, 2016

Three speakers will highlight importance of effective smoking cessation and lung cancer screening programs, as well as practical strategies for implementing these programs during a June 4 Education Session.

Read more

May 26, 2016

Grace K. Dy, MD, discusses clinical trials in progress that evaluate the roles of PD-1/PD-L1 inhibitors in the adjuvant setting for non–small cell lung cancer.

Read more
May 30, 2015

The rise of e-cigarette usage has provoked vigorous debate within the public health community and among health care providers, despite the common goal of getting patients to be completely smoke and vape free.

Read more
June 1, 2015

New recommendations will include a large guideline update on the use of systemic treatment for patients with stage IV non–small cell lung cancer and cover the rapidly advancing area of molecular testing for patients with either early-stage or advanced lung cancer.

Read more
May 31, 2015

Results from the phase III IFCT-GFPC-0701 MAPS trial found that the addition of bevacizumab to standard chemotherapy in patients with malignant pleural mesothelioma prolonged overall survival by 2.75 months.

Read more
May 31, 2015

The high-affinity, humanized monoclonal PD-1 antibody pembrolizumab showed promising antitumor activity in heavily pretreated, PD-L1-positive patients with extensive-stage small cell lung cancer in the KEYNOTE-028 trial.

Read more
May 31, 2015

In patients with advanced nsNSCLC, a chemotherapy regimen including pemetrexed had a better safety profile than one including etoposide, but demonstrated no improvement in survival outcomes. Routine use of the regimen may be questionable, given its considerably higher cost.

Read more